The U.S. Food and Drug Administration (FDA) announced today that it has approved the use of ivacaftor (Kalydeco™) to treat people with cystic fibrosis ages 6 and older who have the R117H mutation.
Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $15 million research agreement with biopharmaceutical company Shire plc to support the development of a new cystic fibrosis treatment targeting the underlying cause of the disease.
At this year's 28th North American Cystic Fibrosis Conference, the CF Foundation's first Mary M. Kontos Care Champion Award was presented to two exemplary nurse coordinators.
Nine cystic fibrosis care centers were awarded the 2013 - 2014 Cystic Fibrosis Quality Care Award for outstanding service to people with CF and their families at the 28th annual North American Cystic Fibrosis Conference in Atlanta.
The recipients of this year's Richard C. Talamo Distinguished Clinical Achievement Award, presented at the 2014 North American Cystic Fibrosis Conference, represent a successful collaboration between researchers and clinicians to bring about a significant advance in CF care and treatment. The award is one of the highest honors given by the Cystic Fibrosis Foundation.
More than 4,000 cystic fibrosis researchers and caregivers marked the 25th anniversary of the discovery of the CF gene at the 28th annual North American Cystic Fibrosis Conference (NACFC) in Atlanta. Attendees shared information on the latest in CF research and discussed the remarkable progress in treating the disease since that historic milestone.
In the largest forum of its kind, more than 4,000 doctors, scientists and caregivers from around the world are meeting today in Atlanta for the 28th annual North American Cystic Fibrosis Conference (NACFC).
This morning, Vertex Pharmaceuticals announced the results from the Phase 3 clinical trials of ivacaftor (Kalydeco™) and lumacaftor (VX-809) in people with two copies of the F508del mutation.
Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), an affiliate of the Cystic Fibrosis Foundation, announced it will extend funding for continued collaboration with Proteostasis Therapeutics, Inc., for the development of new therapies to treat the most common CF mutation, Delta F508.